PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15908476-8	2005	In parallel, lisinopril treatment limited TGF-beta1 protein release into the alveolar space during endotoxemia.	Lisinopril	13-23	transforming growth factor, beta 1	Rattus norvegicus	42-51	
26866372-5	2016	Both lisinopril (ACEi) and MSC treatment prevented monocyte infiltration, reduced tubular cell apoptosis, renal fibrosis and TGFbeta expression.	Lisinopril	5-15	transforming growth factor, beta 1	Rattus norvegicus	125-132	
9506682-14	1998	TGF-beta1 mRNA levels in kidneys of ATS rats were 3.6-fold higher than those of controls and were reduced by 46% and 32% after treatment with lisinopril and L-158,809, respectively.	Lisinopril	142-152	transforming growth factor, beta 1	Rattus norvegicus	0-9	
15106813-6	2004	RESULTS: Lisinopril dose-dependently reduced ACE activity in control and TGF-beta1-treated cardiac fibroblasts.	Lisinopril	9-19	transforming growth factor, beta 1	Rattus norvegicus	73-82	
15106813-9	2004	TGF-beta1 (600 pmol/l) increased (P < 0.05) the production of soluble and non-soluble collagen, and this effect was decreased (P < 0.05) by lisinopril.	Lisinopril	146-156	transforming growth factor, beta 1	Rattus norvegicus	0-9	
12671898-7	2003	High doses of lisinopril suppressed the overexpression of TGF-beta1 mRNA measured by reverse-transcription polymerase chain reaction (RT-PCR) and decreased the number of alpha-SMA-positive cells (activated pancreatic stellate cells) in the pancreas.	Lisinopril	14-24	transforming growth factor, beta 1	Rattus norvegicus	58-67	
12138278-8	2002	Also, the level of gene expression of transforming growth factor-beta (TGF-beta) and plasminogen activator inhibitor-1 (PAI-1) in the renal cortex were reduced, suggesting that lisinopril improved extracellular matrix (ECM) metabolism.	Lisinopril	177-187	transforming growth factor, beta 1	Rattus norvegicus	71-79	
12138278-10	2002	Suppression of TGF-beta and PAI-1 expression contributed to the preventive effect of lisinopril on ECM deposition in renal tissue.	Lisinopril	85-95	transforming growth factor, beta 1	Rattus norvegicus	15-23	
9506682-15	1998	Urinary TGF-beta1 excretion increased in ATS (37.3+/-6.0 ng/d v controls, 13.8+/-3.4 ng/d; P< 0.01) but was normalized by lisinopril and L-158,809 (7.6+/-1.9 ng/d and 6.4+/-0.4 ng/d, respectively; P < 0.01).	Lisinopril	125-135	transforming growth factor, beta 1	Rattus norvegicus	8-17